pubmed.ncbi.nlm.nih.gov

Cytisine for smoking cessation: a literature review and a meta-analysis - PubMed

Review

Cytisine for smoking cessation: a literature review and a meta-analysis

Jean-François Etter. Arch Intern Med. 2006 Aug.

Abstract

Background: Cytisine is an agonist of nicotinic receptors; in particular, it binds strongly with alpha(4)beta(2) nicotinic receptors. Cytisine has been used to treat tobacco dependence for 40 years in Eastern Europe. The objective of this study was to review the literature on the effect of cytisine on smoking cessation.

Methods: Review of PubMed, EMBASE, Psychological Abstracts, BIOSIS, Google.com, and Scholar.google.com, using the keywords cytisine, cytisin, zytisin, cytisinum, Tabex, and smoking cessation. Experts and the manufacturer of Tabex were contacted. Placebo-controlled trials were included in a meta-analysis.

Results: Ten studies reported the effects of cytisine on smoking cessation, including 4 controlled studies (3 placebo controlled). Nine studies used the Bulgarian drug Tabex, containing 1.5 mg of cytisine per tablet, and one Russian study used buccal films containing either 1.5 mg of cytisine or 0.75 mg of cytisine plus 0.75 mg of anabasine. All studies were published between 1967 and 2005 in Bulgaria, Germany, Poland, and Russia. There were 4404 smokers treated with cytisine and 3518 in control conditions. The pooled odds ratio after 3 to 8 weeks in the 3 placebo-controlled trials (2 were double blind and 1 was randomized) was 1.93 (95% confidence interval, 1.21-3.06). For the 2 placebo-controlled double-blind trials with a longer follow-up, the pooled odds ratio after 3 to 6 months was 1.83 (95% confidence interval, 1.12-2.99). One placebo-controlled double-blind trial had follow-up after 2 years (odds ratio, 1.77; 95% confidence interval, 1.29-2.43). Some adverse effects were reported. Most trials were, however, of poor quality.

Conclusions: Cytisine may be effective for smoking cessation. This fact remained largely unnoticed in the English-language literature.

PubMed Disclaimer

Comment in

New weapon to curb smoking: no more excuses to delay treatment.
Johnson BA. Johnson BA. Arch Intern Med. 2006 Aug 14-28;166(15):1547-50. doi: 10.1001/archinte.166.15.1547. Arch Intern Med. 2006. PMID: 16908786 No abstract available.

Cited by

Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence.
Burke MV, Hays JT, Ebbert JO. Burke MV, et al. Patient Prefer Adherence. 2016 Apr 1;10:435-41. doi: 10.2147/PPA.S83469. eCollection 2016. Patient Prefer Adherence. 2016. PMID: 27099479 Free PMC article. Review.
Development of Dependence in Smokers and Rodents With Voluntary Nicotine Intake: Similarities and Differences.
Chellian R, Behnood-Rod A, Bruijnzeel AW. Chellian R, et al. Nicotine Tob Res. 2023 Jun 9;25(7):1229-1240. doi: 10.1093/ntr/ntac280. Nicotine Tob Res. 2023. PMID: 36482774 Free PMC article. Review.
Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
Rollema H, Shrikhande A, Ward KM, Tingley FD 3rd, Coe JW, O'Neill BT, Tseng E, Wang EQ, Mather RJ, Hurst RS, Williams KE, de Vries M, Cremers T, Bertrand S, Bertrand D. Rollema H, et al. Br J Pharmacol. 2010 May;160(2):334-45. doi: 10.1111/j.1476-5381.2010.00682.x. Epub 2010 Mar 22. Br J Pharmacol. 2010. PMID: 20331614 Free PMC article.
Neurobiological Mechanisms of Nicotine Reward and Aversion.
Wills L, Ables JL, Braunscheidel KM, Caligiuri SPB, Elayouby KS, Fillinger C, Ishikawa M, Moen JK, Kenny PJ. Wills L, et al. Pharmacol Rev. 2022 Jan;74(1):271-310. doi: 10.1124/pharmrev.121.000299. Pharmacol Rev. 2022. PMID: 35017179 Free PMC article. Review.
A preliminary benefit-risk assessment of varenicline in smoking cessation.
Cahill K, Stead L, Lancaster T. Cahill K, et al. Drug Saf. 2009;32(2):119-35. doi: 10.2165/00002018-200932020-00005. Drug Saf. 2009. PMID: 19236119 Review.

Cytisine for smoking cessation: a literature review and a meta-analysis - PubMed